Last week, in part 1, I talked about the snow job that the mainstream and FDA have done on safe and effective colloidal silver.

     However, when it comes to warning and scaring people away from silver, both the mainstream medical industry and the FDA have serious credibility problems. First of all, silver has a history of safe and effective use dating back thousands of years. In addition, it continues to be widely used today, including being used by NASA, the US military and Potters for Peace for water purification, being used as a germicidal agent by hospitals and medical suppliers and was recently incorporated into a new line of hospital pajamas to prevent the spread of infection, to name just a few of its present day uses.

     The biggest credibility problem of all for mainstream medicine and the FDA regarding silver is likely how they both approved and embraced silver for medicinal use at one time - yet now would have us believe that silver is both ineffective and dangerous. At one time silver products were very much in favor with both mainstream medicine and the FDA. No fewer than 34 different prescribed over-the-counter medications containing silver were not only widely sold by industry, they were also approved by the very same FDA which now seeks to warn us of its dangers and have us believe it is ineffective.

     What changed their minds? Perhaps the obvious answer can be found in the fact that silver fell out of favor at the very same time that patented sulfa drugs and patented antibiotics created in drug company labs came on the market. Once that happened, the non-patentable silver was no longer a tool for healing, but a threat to profits.

     Zealous protection of mainstream approved drugs and suppression of natural competition is nothing new -look at the estimated 60,000 or more deaths caused by Vioxx before the FDA finally removed it from the market. Look at the ridiculous actions of the FDA when it threatened Washington cherry growers for telling the truth about the health benefits of eating cherries, or at the storm trooper actions against the makers of Charantia (bitter melon) tea in Florida who dared put references to some of the 650 plus PubMed studies and citations about bitter melon on their website.

     The FDA persecutions and prosecutions of cherry farmers, bitter melon, and a long line of other natural alternatives points out just how extreme the protection of the big drug companies' products and profits really is. Consider this: other than issues of national security, only in natural health is it a crime to tell the truth due to the way the FDA has construed their rules and definitions to protect industry. For example, if a company were to advertise that vitamin C was a cure for scurvy, as everyone knows is true, that company could be prosecuted for selling unapproved drugs. The same would be true if a company printed a testimonial from someone who reported health benefits due to vitamin C, or any other vitamin, mineral, supplement or non-FDA-approved drug.

For example, only the makers of FDA approved drugs can use the word cure, or even imply any health benefits without the FDA considering the product a drug. The catch is that in order to be FDA approved, no matter how many PubMed cited studies or other studies have been performed, and no matter how much of a history of hundreds or thousands of years and users, the FDA only approves drugs that go through its specific approval process – one that costs hundreds of billions of dollars.

     When it comes to natural alternatives, spending such money on a natural product is prohibitive, since it could not be patented and could be freely and cheaply sold by any number of competitors and it would be virtually impossible to ever recover all the costs of getting the natural product approved. Though the process is purported to be one which protects the public from unsafe medicines (and we see how well that worked for the hall of shame list of drugs like Vioxx, Avandia, etc.), the net effect of the FDA's drug definitions and approval process is to exclude natural competition and insure that only the patentable and profitable synthetics created in drug company labs can be approved and marketed as having health benefits.

     An example of such one-sided treatment favoring industry came in the following news story earlier this past week about a lawsuit filed against the FDA by Public Citizen after the FDA ignored years of complaints about the dangers of ruptured tendons caused by one of the drug industry's most powerful and profitable antibiotics:

WASHINGTON, D.C. – Despite long-standing evidence that fluoroquinolone antibiotics can cause tendon ruptures, the Food and Drug Administration (FDA) has failed to increase its warnings to patients and physicians about the dangers of the medicines, Public Citizen told a federal court Thursday.

Public Citizen sued in the U.S. District Court for the District of Columbia, asking the court to force the FDA to act upon a petition the consumer group filed with the agency 16 months ago. The FDA has failed to respond to the petition, which asked the agency to put a "black box" warning on fluoroquinolone antibiotics (such as Cipro, Levaquin and others) to make doctors and patients more aware of the risk of serious tendon injury before tendons actually rupture.

The petition also urged the FDA to send a warning letter to physicians, as well as require an FDA-approved medication guide to be dispensed when prescriptions are filled. Public Citizen contends that the FDA is violating the Administrative Procedure Act by not acting upon the petition.

Stronger warnings could lead to earlier intervention and prevent needless injuries by allowing doctors to switch patients to other antibiotics, said Dr. Sidney Wolfe, director of Public Citizen's Health Research Group.

"While the FDA sits idly by and ignores the problem, more people will suffer serious tendon ruptures that could have been prevented," Wolfe said. "The current warning is buried in a long list of possible adverse reactions and is far too easy to miss."

From November 1997 through December 2005, the FDA received 262 reports of tendon ruptures, mainly of the Achilles tendon, 258 cases of tendinitis and 274 cases of other tendon disorders in patients using fluoroquinolone antibiotics. An additional 74 tendon ruptures have subsequently been reported to the FDA for a total of 336. Because only a small fraction of cases are typically reported to the FDA, the actual number of ruptures and other tendon injuries attributable to the antibiotic is much higher

(Source: Healthy News).

     One can only imagine the FDA's reaction if 336 tendon ruptures had been reported for those who take the best antibiotic and pathogen destroyer on the planet - colloidal silver. No doubt, they would have raided the manufacturer with storm troopers and shut it down years ago, just as they have done many times with the manufacturers and sellers of other natural competitors to drug company products.

     In conclusion, as far as I can tell, not one single instance of Argyria has been attributed to properly made colloidal that was not consumed in amounts that were up to hundreds of times the recommended dosage. However, that has not stopped the FDA from continuing to "sing the blues" about silver or from going after those who make and sell colloidal silver products - not because silver represents a whit of threat to human health but rather because it represents a threat to the inflated bottom line profits of the mainstream drug manufacturers.

     Finding out who the FDA really serves is a simple task - all you have to do is follow the money. But don't simply take my word, let a noted past FDA commissioner tell you very clearly what the FDA is really about:

"The FDA 'protects' the big drug companies and are subsequently rewarded, and using the government's police powers they attack those who threaten the big drug companies. People think that the FDA is protecting them.

It isn't.

What the FDA is doing and what the public thinks it is doing are as different as night and day."

Dr. Herbert Ley Former U.S. FDA Commissioner

Printer-friendly version